Skip to contentpdufa.bio

ZYNLONTA (fixed-duration monotherapy)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

ZYNLONTA (fixed-duration monotherapy) is an ADC Therapeutics SA program in relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). Its next catalyst is a Readout on Dec 13, 2026.

ADCT catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indications under review: relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL); relapsed/refractory large B-cell lymphoma; relapsed/refractory marginal zone lymphoma (MZL). Sponsor: ADC Therapeutics SA (ADCT). We track 3 catalyst events for this program: 3 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Dec 13, 2026ADCTReadout · Dec 14, 2026ADCTReadout · Dec 14, 2026ADCT

Specialist biotech funds holding ADCT, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
Redmile Group11,584,552$14.1 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is ZYNLONTA (fixed-duration monotherapy)'s next FDA decision or readout?

The next tracked catalyst for ZYNLONTA (fixed-duration monotherapy) is a Readout on Dec 13, 2026.

What happened at ZYNLONTA (fixed-duration monotherapy)'s most recent FDA decision?

No FDA decision for ZYNLONTA (fixed-duration monotherapy) is in our archive yet.

What is ZYNLONTA (fixed-duration monotherapy) used for?

In our records ZYNLONTA (fixed-duration monotherapy) is under review or in development for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL); relapsed/refractory large B-cell lymphoma.

Who makes ZYNLONTA (fixed-duration monotherapy)?

ADC Therapeutics SA (ADCT).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.